SCHEMBL376026

SCHEMBL376026

CC1CCC(Nc2cncc(-n3cnc4cc(OCC5(C)COC5)ccc43)n2)CN1C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 6/20 0.45
FLT3 P36888 3/20 0.45
CDK2 P24941 2/20 0.45
GAK O14976 1/20 0.45
RIPK2 O43353 1/20 0.45
ULK1 O75385 1/20 0.45
STK10 O94804 1/20 0.45
PRKD3 O94806 1/20 0.45
MAP4K4 O95819 1/20 0.45
LATS1 O95835 1/20 0.45
PAK4 O96013 1/20 0.45
NTRK1 P04629 1/20 0.45
LCK P06239 1/20 0.45
CDK1 P06493 1/20 0.45
APRT P07741 1/20 0.45
RET P07949 1/20 0.45
PDGFRB P09619 1/20 0.45
PHKG2 P15735 1/20 0.45
NQO2 P16083 1/20 0.45
PDGFRA P16234 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10239804 0.91 IRAK4 (0.43) IRAK4FLT3CDK2GAKRIPK2
SCHEMBL376430 0.83 IRAK4 (0.48) IRAK4FLT3CDK2GAKRIPK2
SCHEMBL376757 0.80 IRAK4 (0.48) IRAK4FLT3CDK2GAKRIPK2
SCHEMBL13494224 0.80 IRAK4 (0.44) IRAK4FLT3CDK2GAKRIPK2
SCHEMBL10239102 0.79 FLT3 (0.48) IRAK4FLT3CDK2GAKRIPK2
SCHEMBL375935 0.74 FLT3 (0.53) IRAK4FLT3CDK2GAKRIPK2
SCHEMBL27030594 0.69 LCK (0.61) IRAK4FLT3CDK2GAKRIPK2
SCHEMBL27030629 0.69 IRAK4 (0.70) IRAK4FLT3CDK2GAKRIPK2
SCHEMBL25294290 0.69 IRAK4 (0.57) IRAK4FLT3CDK2GAKRIPK2
SCHEMBL25260749 0.68 LCK (0.62) IRAK4FLT3CDK2GAKRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518952-B2 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors PFIZER INC. (US) 2013-08-27 US disclosed
EP-2328890-B1 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER (US) 2012-01-25 EP disclosed
US-20110144084-A1 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER INC (US) 2011-06-16 US disclosed
EP-2328890-A1 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS Pfizer Inc. (US) 2011-06-08 EP disclosed
WO-2010016005-A1 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER INC. (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144084-A1 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS CHKA, CSNK1A1, CHKB IRAK4 816/4885FLT3 496/4885CDK2 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.